Fundraising Fox
Seneca Therapeutics, Inc Biotechnology
Blue Bell, US · Founded 2018 · 11 employees on LinkedIn · 5 known investors
Find your way into Seneca Therapeutics, Inc Biotechnology
1,147 people in our graph can introduce you to the Seneca Therapeutics, Inc Biotechnology team.
Sign up to see every warm intro you have to Seneca Therapeutics, Inc Biotechnology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Seneca Therapeutics, Inc Biotechnology team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Seneca Therapeutics develops oncolytic virus immunotherapies, particularly Seneca Valley Virus (SVV-001), for treating aggressive and therapy-resistant solid cancers. The company's pipeline includes both monotherapy and gene-armed viral approaches targeting multiple cancer indications, with an IND application open to begin clinical trials in early 2025.
Founders & leadership
Seneca Therapeutics, Inc Biotechnology was founded in 2018 by Paul L. Hallenbeck.
PL
Paul L. HallenbeckFounder, President and Chief Scientific OfficerPaul Hallenbeck is a biotechnology executive with 25 years of experience in oncology drug discovery and development, including work across antibodies, gene therapy, immunotherapy, and oncolytic viruses from candidate selection through clinical trials and regulatory submissions. He has founded and led multiple biotech companies and programs, holds 35+ patents, and has authored over 30 scientific publications.
CD
Cuong DoExecutive ChairmanCuong Do has held executive and strategic roles in pharmaceuticals and technology companies, with 17 years of management consulting experience in healthcare, high technology, and corporate finance.
Board
MK
Mark KerschnerBoard director
Investors · 5
Delaware Crossing Investor Grouplisted by Delaware Crossing Investor GroupPhiladelphia
How we know: Delaware Crossing Investor Group's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$11M disclosed across 5 of 6 rounds · 2019–2024
▶$1.6MraisedFeb 2025 · 68 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedFeb 2025 · 68 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Cuong DoExecutive Officer, Director
- Mark KerschnerDirector
- Paul HallenbeckExecutive Officer, Director
- James HusseyExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $1.6M
- Sales commissions
- $65.5K
- Placement agents
- Walter Greenblatt & Associates, LLC
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.7MraisedDec 2022 · 114 investors · PharmaceuticalsRule 506(b)
▶$7.7MraisedDec 2022 · 114 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James HusseyExecutive Officer, Director
- Paul HallenbeckExecutive Officer, Director
- Mark KerschnerExecutive Officer, Director
- Offering amount
- $12.8M
- Amount sold
- $7.7M
- Sales commissions
- $423.5K
- Proceeds to insiders
- $400K
- Placement agents
- Walter Greenblatt & Associates, LLC
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$501KraisedJun 2020 · 15 investors · PharmaceuticalsRule 506(b)
▶$501KraisedJun 2020 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul HallenbeckExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $501K
- Sales commissions
- $227.5K
- Proceeds to insiders
- $150K
- Placement agents
- Walter Greenblatt & Associates, LLC
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$820KraisedMar 2020 · 14 investors · PharmaceuticalsRule 506(b)
▶$820KraisedMar 2020 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul HallenbeckExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $820K
- Sales commissions
- $70K
- Proceeds to insiders
- $33.7K
- Placement agents
- Walter Greenblatt & Associates, LLC
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$380KraisedAug 2019 · 7 investors · PharmaceuticalsRule 506(b)
▶$380KraisedAug 2019 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul HallenbeckExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $380K
- Sales commissions
- $35K
- Proceeds to insiders
- $90.4K
- Placement agents
- Walter Greenblatt & Associates, LLC
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Seneca Therapeutics, Inc Biotechnology do?
- Seneca Therapeutics develops oncolytic virus immunotherapies, particularly Seneca Valley Virus (SVV-001), for treating aggressive and therapy-resistant solid cancers. The company's pipeline includes both monotherapy and gene-armed viral approaches targeting multiple cancer indications, with an IND application open to begin clinical trials in early 2025.
- Who founded Seneca Therapeutics, Inc Biotechnology?
- Seneca Therapeutics, Inc Biotechnology was founded by Paul L. Hallenbeck in 2018.
- Who are Seneca Therapeutics, Inc Biotechnology's investors?
- Seneca Therapeutics, Inc Biotechnology's investors include Broad Street Angels, Delaware Crossing Investor Group, Dellin Investments, Keiretsu Forum, NW Angel.
- How much funding has Seneca Therapeutics, Inc Biotechnology raised?
- Seneca Therapeutics, Inc Biotechnology has disclosed $11M raised across 5 of its 6 known rounds.
- Where is Seneca Therapeutics, Inc Biotechnology headquartered?
- Seneca Therapeutics, Inc Biotechnology is headquartered in Blue Bell, US.